Prognostic value of a computer-aided diagnosis system involving bone scans among men treated with docetaxel for metastatic castration-resistant prostate cancer by unknown
RESEARCH ARTICLE Open Access
Prognostic value of a computer-aided
diagnosis system involving bone scans
among men treated with docetaxel for
metastatic castration-resistant prostate
cancer
Koichi Uemura1†, Yasuhide Miyoshi1*† , Takashi Kawahara1, Shuko Yoneyama1, Yusuke Hattori1, Jun-ichi Teranishi1,
Keiichi Kondo1, Masatoshi Moriyama2, Shigeo Takebayashi3, Yumiko Yokomizo4, Masahiro Yao4, Hiroji Uemura1 and
Kazumi Noguchi1
Abstract
Background: The bone scan index (BSI), which is obtained using a computer-aided bone scan evaluation system, is
anticipated to become an objective and quantitative clinical tool for evaluating bone metastases in prostate cancer.
Here, we assessed the usefulness of the BSI as a prognostic factor in patients with metastatic castration-resistant
prostate cancer (mCRPC) treated using docetaxel.
Methods: We analyzed 41 patients who received docetaxel for mCRPC. The Bonenavi system was used as the
calculation program for the BSI. The utility of the BSI as a predictor of overall survival (OS) after docetaxel was
evaluated. The Cox proportional hazards model was used to investigate the association between clinical variables
obtained at docetaxel treatment, namely PSA, patient age, liver metastasis, local therapy, hemoglobin (Hb), lactase
dehydrogenase (LDH), albumin (Alb), PSA doubling time, and BSI and OS.
Results: The median OS after docetaxel therapy was 17.7 months. Death occurred in 22 (53.7 %) patients; all deaths were
caused by prostate cancer. In multivariate analysis, three factors were identified as significant independent prognostic
biomarkers for OS after docetaxel; these were liver metastases (yes vs no; HR, 3.681; p = 0.026), Alb (<3.9 vs ≥3.9; HR, 3.776;
p = 0.020), and BSI (>1 % vs ≤1 %; HR, 3.356; p = 0.037). We evaluated the discriminatory ability of our models including or
excluding the BSI by quantifying the c-index. The BSI improved the c-index from 0.758 to 0.769 for OS after docetaxel.
CRPC patients with a BSI >1 had a significantly shorter OS than patients with a BSI ≤1 (p = 0.029).
Conclusions: The BSI, liver metastases and Alb were independent prognostic factors for OS after docetaxel. The BSI might
be a useful tool for risk stratification of mCRPC patients undergoing docetaxel treatment.
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Background
Huggins and Hodges [1] reported the efficacy of androgen
deprivation therapy for advanced prostate cancer in 1941.
Although 80–90 % of prostate cancers with metastasis
respond to initial androgen ablation therapy, most patients
finally develop metastatic castration-resistant prostate
cancer (mCRPC) [2, 3]. Patients with mCRPC exhibit pro-
gression of systemic symptoms and local complications.
Docetaxel is a survival-prolonging chemotherapy drug
used to treat mCRPC patients. Two clinical trials, TAX327
and SWOG99-16, have reported a 20–30 % relative
improvement in overall survival (OS) relative to mitoxan-
trone, with a median improvement of 2–3 months [4–6].
There have been many reports from Asia and Western
countries regarding prognostic factors and risk classification
in relation to docetaxel treatment [7–20]. In a previous
study, we reported risk factors for mCRPC patients before
docetaxel treatment [18]. In results, pain, visceral metasta-
sis, anemia and progression of bone metastasis were found
to be independent prognostic factors for OS after docetaxel.
In relation to these prognostic factors “bone metastasis pro-
gression” is a subjective variable; thus, an objective and
quantitative scoring system for bone metastasis evaluation
would potentially be a strong prognostic factor. Recently, a
computer-aided diagnosis system (Bonenavi) for bone scans
has been developed. This system can be used to calculate
the bone scan index (BSI); this provides an objective and
quantitative measure of the percentage of the skeleton
affected by bone metastases [21]. Mitsui et al. found that
patients with a decreased BSI after taxane-based chemo-
therapy had significantly longer OS than other patients
[22]. They also reported that patients with a BSI ≥3.0 % had
reduced survival relative to men with a BSI <3.0 % in the
same cohort. In our study, we analyzed the relationship
between mCRPC prognosis and clinicopathological factors,
including the BSI calculated using the Bonenavi system for
OS after docetaxel. The aim of our study was to determine
if BSI could be a useful prognostic marker for mCRPC pa-
tients undergoing docetaxel treatment.
Methods
Study design, patients and treatments
We retrospectively analyzed 41 patients who were treated
with docetaxel for mCRPC between 2011 and 2014 at
Yokohama City University Medical Center and Yokohama
University Hospital. Patient characteristics are listed in
Table 1. Of the patients, 22 had only bone metastasis, 8 had
lymph node + bone metastasis, 2 had lung + lymph node +
bone metastasis, 3 had lung + bone metastasis, and 6 had
liver + lymph node + bone metastasis. The initial median
PSA value was 176.0 ng/ml and the PSA level at docetaxel
induction was 56.8 ng/mL. The median BSI was 2.4 %
(range, 0.0–12.2 %). All patients had histologically con-
firmed prostate adenocarcinoma. The 2009 TNM clinical
staging system and 2005 International Society of Urologic
Pathology Gleason grading system were used [23]. In all
patients, clinical stage was evaluated using chest and body
computed tomography and bone scans at initial treatment,
and before docetaxel treatment.
Each hospital used the same treatment protocol. All
patients were initially treated with androgen deprivation
therapy (medical or surgical castration with anti-androgen).
After initial androgen ablation therapy failed, almost all
patients were given anti-androgen withdrawal therapy, sub-
sequent substitution treatment comprising anti-androgen
therapy (bicalutamide to flutamide), followed by docetaxel
with dexamethasone. Patients were treated with 60 mg/m2
docetaxel IV on day 1, given over 1 h, every 21 days. All
patients received continuous androgen ablation therapy (an
LH-RH analogue) and 0.5 mg dexamethasone orally. Treat-
ment was continued until disease progression or unaccept-
able adverse events occurred.
Some patients received bisphosphonate or denosumab
after the development of CRPC. No patients received
abiraterone, enzalutamide or cabazitaxel because these
drugs were not approved until 2013. For patients at the
terminal stage, palliative therapy and pain control with
morphine, palliative external beam radiotherapy, and
strontium were used as appropriate. Serum PSA levels
were measured using the Elecsys PSA Assay (Roche
Diagnostics Corp., Basle, Switzerland).
BSI
Bone scan images were obtained within 1 month before
or after docetaxel treatment induction. The automated
method for analysis of anterior and posterior whole-
body bone scan images has been described previously
[24]. Each individual hot spot was classified as a metas-
tasis or not a metastasis using an artificial neural
network (ANN), and the BSI was calculated as the per-
centage of the sum of all hot spots classified as bone
metastases using the ANN values. To calculate the BSI,
we used Bonenavi version 2 (Fujifilm RI Pharma Co.
Ltd., Tokyo, Japan; Exini Bone, Exini Diagnostics, Lund,
Sweden) [25].
Statistical analysis
We compared ALP or EOD and BSI levels using Pearson’s
correlation coefficient. If some factors were found to be
correlated with other factors, the correlated factors were
not analyzed simultaneously because of multicollinearity.
We investigated the usefulness of a BSI as a predictor of
survival after docetaxel treatment. The Cox proportional
hazards model with stepwise regression analysis was used
to investigate the association between clinical variables
obtained at docetaxel treatment namely PSA, patient age,
liver metastasis, local therapy, hemoglobin (Hb), lactase
dehydrogenase (LDH), albumin (Alb), PSA doubling time,
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BSI and survival. The cutoff point for PSA, patient age, Hb,
LDH, Alb and PSADT were determined using the median
value of each variable. The cutoff point for the BSI was set
at 1.0 % according to a report by Ulmert and colleagues
[24].
Relative risks and 95 % confidence intervals were derived.
The C-index was used regarding the discriminatory ability
of our models.
To calculate the PSA doubling time (PSADT), two con-
secutive PSA values, spaced 1 month apart after docetaxel
induction therapy, were used. PSADT was calculated
using the natural log of 2 (0.693) divided by the slope of
the relationship between the log of PSA and the time of
PSA measurement for each patient [26].
The Kaplan–Meier product-limit estimator was used
to estimate the survival distribution. The log-rank test
was used for analysis of the survival differences.
All tests were two-sided, and the significance level was
fixed at alpha = 0.05. All analyses were conducted using
IBM SPSS Statistics software for Windows, version 22
(IBM Corp., Armonk, NY, USA) and the R stats package
(R Foundation for Statistical Computing, Vienna, Austria).
The experimental procedures were conducted in
accordance with the ethical standards of the Helsinki
Declaration. This study was approved by the institutional
review board of Yokohama City University Medical Cen-
ter. Informed consent to participate in the study were
obtained from participants
Results
In our cohort, death occurred in 22 patients (53.7 %); all
deaths were caused by prostate cancer. The median OS
after docetaxel therapy was 17.7 (95 % confidential inter-
val [CI]: 10.6–24.9; range, 1.7–51.0) months (Fig. 1).
The correlation of EOD classification and the BSI is
shown in Fig. 2. There was a significant correlation
between EOD and the BSI (r = 0.693). A significant
correlation between serum alkaline phosphatase (ALP)
levels and the BSI was also observed (r = 0.643, Fig. 3).
Because of the strong correlations, we did not analyze
the BSI, serum ALP levels, and EOD in multivariate ana-
lysis simultaneously owing to multicollinearity.
In multivariate analysis, three factors were identified
as independent prognostic biomarkers for OS after doce-
taxel therapy as follows: liver metastases (yes vs no; HR,
3.681; 95 % CI, 1.166–11.616; p = 0.026), Alb (<3.9 g/dL
Table 1 Patient characteristics (n = 41)
Variables before primary androgen
deprivation therapy
Median initial PSA, ng/mL (range) 176.0 (4.2-6500.0)
Gleason scores, n (%)
6-7 4 (9.8 %)
8-10 37 (90.2 %)
Clinical T, n (%)
≤T3 32 (78.0 %)
T4 9 (22.0 %)
Clinical N, n (%)
N0 14 (34.1 %)
N1 27 (65.9 %)
Clinical M, n (%)
M0 12 (29.3 %)
M1a 5 (12.2 %)
M1b 21 (51.2 %)
M1c 3 (7.3 %)
EOD, n (%)
0 17 (41.5 %)
1 4 (9.8 %)
2 4 (9.8 %)
3 7 (17.1 %)
4 9 (22.0 %)
Variables at docetaxel therapy
induction
Median PSA, ng/mL (range) 56.8 (0.2-4715.0)
Median PSA doubling time,
months (range)
1.4 (−3.8-47.1)
Median LDH, IU/L (range) 225 (135–1129)
Median Hb, g/dL (range) 11.7 (8.1-13.7)
Median Alb, g/dL (range) 3.9 (2.4-4.7)
Median ALP, IU/L (range) 278 (135–3296)







Median BSI, % (range) 2.4 (0.0-12.2)
BSI ≤1 %, n (%) 18 (43.9 %)
BSI >1 %, n (%) 23 (56.1 %)
Liver metastasis, n (%)
Yes 6 (14.96 %)
No 35 (85.4 %)
Table 1 Patient characteristics (n = 41) (Continued)
Local therapy (prostatectomy
or radiation), n (%)
Yes 5 (12.2 %)
No 36 (87.8 %)
PSA prostate-specific antigen, LDH lactate dehydrogenase, Hb hemoglobin, Alb
albumin, BSI bone scan index
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vs ≥3.9 g/dL; HR, 3.776; 95 % CI, 1.238–11.516; p = 0.020),
and BSI (>1 % vs ≤1 %; HR, 3.356; 95 % CI, 1.078–10.453;
p = 0.037) (Table 2).
We evaluated the discriminatory ability of our models by
quantifying the c-index. The c-index in our model includ-
ing the BSI was 0.769 in the prediction of OS after doce-
taxel therapy. We also analyzed the discriminatory ability
of the model excluding BSI by quantifying the c-index. The
c-index of the model excluding BSI was 0.758 for the
prediction of OS. In predicting OS, the c-index of the
model including the BSI was higher relative to the model
excluding the BSI.
We compared the survival probability by BSI categories.
The median OS was 26.5 months in patients with a BSI
Fig. 1 Kaplan–Meier curve for overall survival (OS) after docetaxel induction therapy. The median OS after docetaxel was 17.7 months
Fig. 2 Correlation of EOD classification and the BSI. Box plots indicate the first and third quartiles. The band inside the box shows the median.
Lines extending vertically from the boxes (whiskers) indicate variability outside the upper and lower quartiles. There was a significant correlation
between EOD and the BSI (r = 0.693). BSI; bone scan index, EOD; extent of disease on bone scan
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≤1 and 15.4 months in patients with a BSI >1 (p = 0.029).
Patients with a BSI >1 had a significantly shorter OS than
patients with BSI ≤1 (Fig. 4).
We stratified the patients into two cohorts with low
risk (0–1 risk factor present) and high risk (2–3 risk
factors present). The risk factors in each risk group were
shown in Table 3. We found a statistically significant
difference in OS after docetaxel treatment among risk
groups (Fig. 5; p < 0.000).
Discussion
In this study, we reported the usefulness of BSI which
calculated by computer-aided diagnosis system involving
bone scans as prognostic biomarker in CRPC patients,
although the routine use of bone scan in CRPC treatments
remains controversial. Recently, clinical significance of
imaging in CPRC treatments have been increasing and
developing rapidly. Several studies demonstrated the
usefulness of the PET/CT both for restaging and for asses-
sing the response to treatment in CRPC patients [27–29].
Several groups have reported prognostic models for the
survival of patients with castration-resistant prostate
cancer. Armstrong and colleagues reported that a decrease
of 30 % in PSA level, visceral metastasis, anemia and bone
scan progression were independent prognostic factors in
docetaxel-treated patients with CRPC [20]. We have also
Fig. 3 Correlation of ALP levels and the BSI. There was a strong correlation between serum ALP levels and the BSI (r = 0.643). ALP; alkaline
phosphatase, BSI; bone scan index
Table 2 Univariate and multivariate analysis of overall survival after the administration of docetaxel
Variables at docetaxel
induction
Univariate analysis Multivariate analysis
p value Hazard
ratio
95.0 % CI p value Hazard
ratio
95.0 % CI
Lower Upper Lower Upper
PSA (≥56.8 ng/mL vs <56.8) 0.115 1.991 0.845 4.693 0.894 0.929 0.317 2.729
Age(>73 vs ≤73) 0.623 0.810 0.349 1.879 0.944 0.964 0.343 2.704
Liver mets (yes vs no) 0.239 1.825 0.670 4.969 0.026 3.681 1.166 11.616
Local therapy (yes vs no) 0.137 0.218 0.029 1.624 0.206 0.213 0.019 2.339
Hb (<11.7 g/dL vs ≥11.7) 0.072 0.457 0.194 1.072 0.887 1.073 0.404 2.850
LDH (>225 IU/L vs ≤225) 0.045 2.385 1.019 5.578 0.078 2.500 0.903 6.915
Alb (<3.9 g/dL vs ≥3.9) 0.001 5.965 1.987 17.908 0.020 3.776 1.238 11.516
PSADT (≤1.4 months vs >1.4) 0.123 1.971 0.832 4.668 0.888 1.075 0.392 2.948
BSI (>1 % vs ≤1 %) 0.035 2.673 1.072 6.661 0.037 3.356 1.078 10.453
PSA prostate-specific antigen, PSADT PSA doubling time, Hb hemoglobin, LDH lactate dehydrogenase, Alb albumin, BSI bone scan index, Liver mets liver metastasis
The normal ranges of Hb, LDH and Alb were 11.3–14.5 g/dL, 116–199 IU/L and 4.2–5.4 g/dL, respectively
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previously described the risk factors for mCRPC patients
before docetaxel treatment [18]. In results, pain, visceral
metastasis, anemia and bone metastasis progression were
independent prognostic factors for OS after docetaxel
[18]. Because >80 % of mCRPC patients have bone metas-
tases [4, 5], more attention should be given to accurate
evaluation of bone metastases in the consideration of
prognosis. The extent of disease (EOD) score suggested by
Soloway et al. [30] was used for the evaluation of bone
metastasis in prostate cancer. Based on the number or
extent of the metastases, the scans were divided into the
following five grades according to the EOD on bone scan
[30]: 0) normal or abnormal as a result of benign bone
disease; 1) <6 bony metastases, each of which is <50 % of
the size of a vertebral body (one lesion that was approxi-
mately the size of a vertebral body was counted as two
lesions); 2) 6–20 bone metastases, sized as described
above; 3) >20 metastases but fewer than seen in a “super-
scan”; and 4) superscan or its equivalent (i.e., >75 % of the
ribs, vertebrae and pelvic bones). Previously, we analyzed
the relationship between prostate cancer outcomes and
pretreatment clinical factors, and developed a prognostic
survival model for patients with bone metastatic hormone-
naive prostate cancer [31]. In that model, the EOD score
was a strong prognostic factor for survival.
Although the EOD score has important prognostic
information, it is a subjective and semi-quantitative
parameter. For a more accurate and convenient method
for bone metastases evaluation, objective and quantita-
tive markers are required. Accurate evaluation of bone
metastases would lead to an appropriate prediction of
prostate cancer survival probability, and would be valu-
able for patient counseling.
It is anticipated that a BSI that uses a computer-aided
diagnosis system for bone scans will become an objective
and quantitative clinical tool for evaluating bone meta-
static prostate cancer. The BSI has been reported as being
useful as a survival predictor among men with prostate
cancer with various conditions such as hormone-naïve
prostate cancer or CRPC [22, 32–38].
In patients with CRPC, the usefulness of the BSI as a
prognostic marker has been reported. Mitsui et al. found
that patients with a decreased BSI after taxane-based
chemotherapy had significantly longer OS than other
patients [22]. They also reported that patients with a BSI
≥3.0 had reduced survival relative to men with a BSI <3.0
in the same cohort. Koboteh et al. also reported that
patients with a decreased BSI after docetaxel had a better
prognosis than other patients [35]. Dennis et al. reported
that a change in BSI from baseline to 3–6 months after
treatment for CRPC may provide prognostic information
Fig. 4 Kaplan–Meier curve for overall survival (OS) after docetaxel induction therapy according to the bone scan index (BSI). The blue line
indicates survival for patients with a BSI ≤1 (n = 18) and the red line indicates survival for patients with a BSI >1 (n = 23). The median OS of
patients with a BSI ≤1 and a BSI >1 was 26.5 and 15.4 months, respectively (p = 0.029)
Table 3 Distribution of risk factors classified by risk group
Low risk High risk
Risk factors, n 0–1 2–3
Patients, n (%) 25 (61.0 %) 16 (39.0 %)
Alb, <3.9 g/dL, n (%) 6 (14.6 %) 14 (34.1 %)
BSI, >1 %, n (%) 9 (22.0 %) 14 (34.1 %)
Liver mets, yes, n (%) 1 (2.4 %) 5 (12.2 %)
There were no patients with >3 risk factors
Alb albumin, BSI bone scan index, Liver mets liver metastasis
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[33]. Armstrong et al. reported that the BSI, and change in
the BSI over time, were independently associated with OS
in patients with mCRPC in a tasquinimod treatment trial
[32]. Although some studies have demonstrated the use-
fulness of the BSI, unfortunately few have included signifi-
cant clinical information such as blood data and visceral
metastasis. In previous studies, patient age and blood data
such as serum Hb, alkaline phosphatase, LDH and CRP
levels have been reported as predictive factors for patients
with prostate cancer [39–41]. In our study, we analyzed
the correlations between survival and clinical factors
including variables at docetaxel induction therapy (PSA,
patient age, liver metastasis, local therapy, Hb, LDH, Alb,
PSA doubling time, and BSI) using the Cox proportional
hazards regression model. EOD classifications and serum
ALP level were significantly associated with the BSI value;
EOD and serum ALP level were not included in the multi-
variate analysis because of multicollinearity. Three factors
were identified as independent prognostic biomarkers for
OS after docetaxel therapy as follows: liver metastases,
Alb and BSI. Because the BSI has continuous covariations,
it is better suited and accurate in the prediction of individ-
ual patient prognosis relative to EOD classifications.
In addition, we evaluated the discriminatory ability of
our models including or excluding the BSI by quantify-
ing the c-index. The BSI improved the c-index from
0.758 to 0.769 in predicting OS after docetaxel therapy.
Median OS after docetaxel was 26.5 months in patients
with a BSI ≤1 and the median OS after docetaxel was
15.4 months in patients with a BSI >1 (p = 0.029).
Patients with a BSI >1 had a significantly shorter OS
than patients with a BSI ≤1.
Recently, there has been rapid development in the treat-
ment of CRPC. In the United States and other Western
countries, some new effective agents for CRPC have been
approved, including docetaxel, cabazitaxel, radium-223
dichloride, sipuleucel-T, abiraterone and enzalutamide [4,
42–47]. Unfortunately, treatment for CRPC in Japan was
very limited until 2013 (cabazitaxel, abiraterone and enzalu-
tamide were approved in 2014), even though docetaxel was
approved in 2008 [48]. Thus, in our study, none of the
patients received cabazitaxel, sipuleucel-T, abiraterone or
enzalutamide. These agents could improve the survival of
patients with CRPC, and our model could underestimate
the prognosis when these new agents were used for CRPC.
Thus, the first limitation of our study is that our models
were developed using data from the “docetaxel era.” For
more accurate prediction of prognosis in patients with
prostate cancer in the “post-docetaxel era,” more recently
collected data are needed. The second limitation is the fact
that patients enrolled had various health statuses and
complications. Our models considered neither health
status nor patient complications that may influence pros-
tate cancer treatment outcomes [49–51]. Patients with
prostate cancer are much older than those with other
malignancies. Health status and complications should be
classified in the rating score and included as predictive
factors in the prognostic model. Bone pain at diagnosis is
Fig. 5 Kaplan–Meier curve for overall survival (OS) after docetaxel induction therapy according to risk group. We stratified the patients into two
cohorts with low risk (0–1 risk factor present) and high risk (2–3 risk factors present). The blue line indicates survival for patients with low risk
(n = 25) and the red line indicates survival for patients with high risk (n = 16). The median OS of patients with low risk and high risk was 26.5 and
11.5 months, respectively (p < 0.000). The risk factors in each risk group were shown in Table 3
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also a strong predictor of survival [51]. Unfortunately, data
regarding pain at baseline were not available in this study.
Moreover, no information was available on the number of
patients received bisphosphonate or denosumab after the
development of CRPC. Bisphosphonate or denosumab
showed significant effect for reducing the skeletal-related
events and improving progression-free survival although
these agents except clodronate has not been shown to
improve overall survival in randomized phase 3 controlled
trial [52, 53]. Finally, our population was small and obser-
vation periods were relatively short. Evaluation of larger
patient populations and long observations are warranted
to establish the usefulness of the BSI as a prognostic
factor. Although some study limitations exist, the BSI be-
fore treatment might be useful as a prognostic biomarker
for hormone-naïve bone metastatic prostate cancer.
Conclusions
In conclusion, we evaluated the prognostic value of a
computer-aided diagnosis system (Bonenavi) for bone scans
in patients who received docetaxel treatment for mCRPC.
The BSI (calculated using Bonenavi), Alb and liver metasta-
ses were independent prognostic factors for OS after doce-
taxel therapy. BSI might be a useful tool for risk
stratification of patients with mCRPC undergoing docetaxel
treatment.
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